Trastuzumab biosimilar - Celltrion

Drug Profile

Trastuzumab biosimilar - Celltrion

Alternative Names: CT-P06; CT-P6; Herzuma

Latest Information Update: 10 Jun 2017

Price : $50

At a glance

  • Originator Celltrion
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Breast cancer; Gastric cancer

Most Recent Events

  • 04 Jun 2017 Adverse events, efficacy, pharmacokinetics, pharmacodynamic data from a phase III trial in Breast cancer presented at the 53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 11 Apr 2017 Preregistration for Breast cancer in Japan (IV)
  • 31 Oct 2016 Celltrion announces intention to apply for approval for sales to the US FDA for Breast cancer in the first half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top